| Involvement of the mismatch repair system in temozolomide-induced apoptosis S D’Atri, L Tentori, PM Lacal, G Graziani, E Pagani, E Benincasa, ... Molecular pharmacology 54 (2), 334-341, 1998 | 344 | 1998 |
| Systemic administration of GPI 15427, a novel poly (ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma … L Tentori, C Leonetti, M Scarsella, G d’Amati, M Vergati, I Portarena, W Xu, ... Clinical Cancer Research 9 (14), 5370-5379, 2003 | 261 | 2003 |
| Chemopotentiation by PARP inhibitors in cancer therapy L Tentori, G Graziani Pharmacological research 52 (1), 25-33, 2005 | 258 | 2005 |
| Potential clinical applications of poly (ADP-ribose) polymerase (PARP) inhibitors L Tentori, I Portarena, G Graziani Pharmacological research 45 (2), 73-85, 2002 | 239 | 2002 |
| Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid C Ceci, PM Lacal, L Tentori, MG De Martino, R Miano, G Graziani Nutrients 10 (11), 1756, 2018 | 204 | 2018 |
| Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis L Tentori, PM Lacal, A Muzi, AS Dorio, C Leonetti, M Scarsella, F Ruffini, ... European Journal of Cancer 43 (14), 2124-2133, 2007 | 179 | 2007 |
| Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer G Graziani, L Tentori, P Navarra Pharmacological research 65 (1), 9-22, 2012 | 174 | 2012 |
| Challenging resistance mechanisms to therapies for metastatic melanoma L Tentori, PM Lacal, G Graziani Trends in pharmacological sciences 34 (12), 656-666, 2013 | 133 | 2013 |
| PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy E Salvati, M Scarsella, M Porru, A Rizzo, S Iachettini, L Tentori, G Graziani, ... Oncogene 29 (47), 6280-6293, 2010 | 130 | 2010 |
| Inhibition of poly (ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma L Tentori, C Leonetti, M Scarsella, A Muzi, E Mazzon, M Vergati, O Forini, ... The FASEB journal 20 (10), 1709-1711, 2006 | 120 | 2006 |
| Essential role of the interleukin 2-interleukin 2 receptor pathway in thymocyte maturation in vivo. L Tentori, DL Longo, JC Zuñiga-Pflucker, C Wing, AM Kruisbeek The Journal of experimental medicine 168 (5), 1741-1747, 1988 | 120 | 1988 |
| Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? L Tentori, G Graziani Pharmacological Research 55 (5), 359-369, 2007 | 119 | 2007 |
| Recent approaches to improve the antitumor efficacy of temozolomide L Tentori, G Graziani Current medicinal chemistry 16 (2), 245-257, 2009 | 113 | 2009 |
| Combined treatment with temozolomide and poly (ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site L Tentori, C Leonetti, M Scarsella, G d'Amati, I Portarena, G Zupi, ... Blood, The Journal of the American Society of Hematology 99 (6), 2241-2244, 2002 | 113 | 2002 |
| CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway G Graziani, L Tentori, I Portarena, M Barbarino, G Tringali, G Pozzoli, ... Endocrinology 143 (3), 807-813, 2002 | 94 | 2002 |
| Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth C Ceci, L Tentori, MG Atzori, PM Lacal, E Bonanno, M Scimeca, R Cicconi, ... Nutrients 8 (11), 744, 2016 | 89 | 2016 |
| Poly(ADP‐ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells L Tentori, I Portarena, F Torino, M Scerrati, P Navarra, G Graziani Glia 40 (1), 44-54, 2002 | 87 | 2002 |
| Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. L Tentori, DM Pardoll, JC Zuniga, J Hu-Li, WE Paul, JA Bluestone, ... Journal of immunology (Baltimore, Md.: 1950) 140 (4), 1089-1094, 1988 | 82 | 1988 |
| Pharmacological inhibition of poly (ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide L Tentori, L Ricci-Vitiani, A Muzi, F Ciccarone, F Pelacchi, R Calabrese, ... BMC cancer 14, 1-12, 2014 | 79 | 2014 |
| Inhibition of O6-alkylguanine DNA-alkyltransferase or poly (ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide L Tentori, L Orlando, PM Lacal, E Benincasa, I Faraoni, E Bonmassar, ... Molecular pharmacology 52 (2), 249-258, 1997 | 78 | 1997 |
